Glenmark Pharmaceuticals has informed that it attached media release on January 20, 2022 titled ‘Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray in for Singapore, Hong Kong and Vietnam.’
The above information is a part of company’s filings submitted to BSE.